摘要
34例躁狂症病人随机分卡马西平治疗组(18例)和碳酸锂对照组(16例),以倍克-拉范森躁狂量表为评定工具。结果表明,wk4末卡马西平治愈率为39％,wk2末和wk4末的量表评分较治疗前减少有显著性差异,wk4末和wk2末的减少无差异。wk2到wk4增加痊愈例数碳酸锂组多于卡马西平组。卡马西平组wk4末情绪、自我评价、工作较其它因子分减少有差异。卡马西平副作用有轻微的恶心,呕吐、腹泻、嗜睡、共济失调。认为卡马西平是一种安全、可靠的抗躁狂药物。
34 cases of mania were treated randomizely with either carbamazepine (n = 18) or lithium carbonate(n = 16). All of them were evaluated with Bech-Rafae-1sen Mania Rating Scale(BRMS) before and after the therapy.Results revealed that the recovery rate was 39% in patient receiving carbamazepine.BRMS scores at the end of second and fourth week following carbamazepine were significantly redu-ced(P<0.01).The responders of lithium from second to fourth week were definitely better than those of carbamazepine.In addition, the scores of emotion, self evaluation and working ability were significantly decreased 4 weeks after given with car-bamazepine.Mild side effects, such as nausea, vomiting, diarrhea, drownsiness and ataxia were occured during the therapy. Accordingly,carbamazepine is considered as a reliable antimanic measure.
出处
《新药与临床》
CSCD
北大核心
1989年第1期12-14,共3页
关键词
卡马西平
碳酸锂
躁狂症
carbamazepine
lithium carbonate
manic disorder
